Aspire Biopharma completes Phase 1 enrollment for its fast-acting sublingual aspirin

Aspire Biopharma completes Phase 1 enrollment for its fast-acting sublingual aspirin

By, Admin 27 June 2025

Overview

Aspire Biopharma Holdings, Inc, developer of a multi-faceted patent-pending drug delivery technology, announced the last patient was dosed in its phase 1 single-center clinical study of its oral transmucosal fast-acting high-dose aspirin formulation.

The timely enrollment- Enrollment is completed on schedule and top-line results from the study are anticipated by the middle of third quarter of 2025.

Statement from Michael Howe: CEO of Aspire

The successful completion of patient dosing in our phase 1 trial is a noteworthy accomplishment. We are extremely grateful to the investigator and patients who participated in this study. Achieving this milestone on time and as planned per protocol also demonstrates the operational excellence of our team and clinical partners,"" said Michael Howe, CEO of Aspire. 
""We look forward to reporting initial safety and efficacy data in the third quarter, which will provide key insights into our formulation of high-dose aspirin and its potential as a fast-acting treatment option for suspected acute myocardial infarction. Following the receipt of the topline results, we plan to continue discussions with the US FDA to ensure our path forward is well-aligned with regulatory expectations.""
Howe added, ""We are eager to integrate the insights from this trial into our comprehensive development plan. We believe these trial results will also play a key role in our strategy to pursue potential partnership opportunities.

Phase 1 trial: Comparing the pharmacokinetic and pharmacodynamic characteristics

  • The phase 1 clinical trial, which is being conducted in the United States, compares the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers after the administration of our sublingual dose of 162.5 mg aspirin powder with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin tablets). 
  • The primary outcome measure will be plasma acetylsalicylic acid (ASA) concentration versus time data (pre-dose and up to 24 hours’ post-dose). 
  • The trial also measures Arachidonic acid (AA)-induced platelet aggregation over 8 hours after dosing and Serum thromboxane B2 (TxB2) over 8 hours after dosing, both of which are valuable for documenting Aspire's sublingual high-dose aspirin's rapid impact on cardiac events.

Plans for NDA approval- Following completion of this trial, Aspire plans to submit a section 505(b)(2) NDA seeking approval to market the high-dose aspirin product.

About Aspire & it’s cutting edge technology

  • Aspire's technology delivers a soluble, fast-acting granular or powder formulation which has been developed by using our patent-pending methodology, and ""trade secret"" process. 
  • The technology's new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream of drugs and other substances. 
  • The benefits of ""rapid absorption"" are to provide rapid impact in more precise quantities.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!